We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Detects Multiple Signs of Brain Cancer

By LabMedica International staff writers
Posted on 25 Jul 2022

Researchers who had previously developed a blood test for mutations in a gene linked to gliomas, the most common type of adult brain tumors, have now applied their technology to detect additional mutations, in this case in the gene that codes for epidermal growth factor receptor (EGFR). More...

The advance provides clinicians with a powerful tool to detect the presence of gliomas, characterize the tumors, and monitor their status after treatment.

The test developed by researchers at Massachusetts General Hospital (MGH, Boston, MA, USA) is a form of liquid biopsy that detects pieces of tumor cells’ genetic material - called mRNA - that are circulating in the blood. A previous study first reported the technique, a highly optimized novel digital droplet polymerase chain reaction (ddPCR) blood test, for accurately detecting and monitoring the presence of two mutations of the gene TERT, which is commonly mutated in glioma tumors. After further tailoring their technique to detect mRNA produced from a mutated EGFR gene called EGFRvIII that is often present in especially aggressive gliomas, the investigators determined the prevalence of EGFRvIII mRNA in glioma tumor tissue from 37 tumor tissue samples, and they tested their blood test in plasma samples from 30 patients with gliomas with tissue-confirmed EGFRvIII, 10 patients with gliomas with no EGFR mutations, and 14 healthy controls. The team reported that the blood test had an overall sensitivity (ability to detect the presence of EGFRvIII) of 72.8% and a specificity (ability to detect the absence of EGFRvIII) of 97.7%.

The technology could also be used to determine which patients are most likely to benefit from drugs targeting the EGFRvIII protein on cancer cells. The scientists note that their EGFR and TERT tests will require additional studies to evaluate their performance in larger groups of patients; however, combining different mutation assays represents a promising strategy to more accurately diagnose gliomas, monitor tumor progression, and assess response to therapy. The technology could also be applied to a range of other cancer types that carry mutations in these and other genes.

“There is a real need to make brain tumor diagnosis less invasive than the current technique of tissue biopsy. This research demonstrates that it is now feasible to diagnosis a brain tumor via a blood test for one of the most common mutations detected in brain tumors,” said co–senior author Leonora Balaj, PhD, an investigator at MGH’s Brain Tumor Research Center and an assistant professor of Neurosurgery at Harvard Medical School.

“Current studies involving CAR-T immune cells are aimed at targeting this surface marker. A blood-based assay for EGFRvIII would allow to stratify patients who would be eligible for potential clinical trials as well as monitor the response to the therapeutic using a simple blood test,” added co–senior author Bob S. Carter, MD, PhD, chair of the Department of Neurosurgery at MGH and the William and Elizabeth Sweet Professor of Neurosurgery at Harvard Medical School.

Related Links:
MGH 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.